Arete Wealth Advisors LLC bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,014 shares of the company’s stock, valued at approximately $498,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRSP. Pinnacle Holdings LLC bought a new stake in shares of CRISPR Therapeutics during the first quarter worth $48,000. Ancora Advisors LLC increased its position in shares of CRISPR Therapeutics by 83.2% during the first quarter. Ancora Advisors LLC now owns 1,156 shares of the company’s stock worth $141,000 after acquiring an additional 525 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $50,000. Bank Julius Baer & Co. Ltd Zurich raised its position in CRISPR Therapeutics by 36.1% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,302 shares of the company’s stock valued at $59,000 after buying an additional 345 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at approximately $55,000. 68.20% of the stock is owned by institutional investors and hedge funds.
CRISPR Therapeutics Price Performance
NASDAQ:CRSP opened at $50.58 on Friday. The company has a market cap of $4.02 billion, a P/E ratio of -9.54 and a beta of 1.62. CRISPR Therapeutics AG has a one year low of $38.94 and a one year high of $73.62. The firm’s fifty day moving average price is $52.39 and its two-hundred day moving average price is $53.39.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on CRSP shares. Credit Suisse Group lifted their target price on CRISPR Therapeutics from $62.00 to $63.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $88.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, August 8th. Chardan Capital cut their price target on shares of CRISPR Therapeutics from $123.00 to $110.00 and set a “buy” rating on the stock in a research report on Monday, August 7th. Citigroup raised shares of CRISPR Therapeutics from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research report on Thursday, August 17th. Finally, StockNews.com assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, August 17th. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $70.94.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Five stocks we like better than CRISPR Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Best Stocks Under $10.00
- MarketBeat Week in Review – 9/11 – 9/15
- Conference Calls and Individual Investors
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.